Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alvocidib + decitabine
- Development stage
- Unknown
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Alvocidib + decitabine is an investigational combination therapy composed of alvocidib, a small-molecule cyclin-dependent kinase 9 (CDK9) inhibitor, and decitabine, a nucleoside analog DNA methyltransferase inhibitor. The combination is being studied for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with the rationale that decitabine-mediated DNA hypomethylation sensitizes cells to apoptosis by inducing NOXA (an antagonist of the anti-apoptotic protein MCL-1), while alvocidib downregulates MCL-1 expression by inhibiting CDK9, potentially leading to synergistic antileukemic activity in MCL-1-dependent malignancies[5]. Clinical trials have explored this sequential regimen in relapsed/refractory and frontline settings for AML and MDS[1][4][5].
02
Targets
CDK1 (Cyclin-dependent kinase 1)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)CDK7CDK9 (Cyclin-dependent kinase 9)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on alvocidib + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alvocidib + decitabine.